The primary efficacy outcome occurred in 79 ( 87 % ) of 905 patients in the bivalirudin group and 52 ( 57 % ) of 907 patients in the heparin group ( absolute risk difference 30 % ; relative risk [ RR ] 152 , 95 % CI 109-213 , p = 001 ) .